A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
ESMO Open - United Kingdom
doi 10.1136/esmoopen-2019-000532
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2019
Authors
Publisher
BMJ